Premium
Feto‐maternal haemorrhage associated with genetic amniocentesis: results of a randomized trial
Author(s) -
TABOR ANN,
BANG JENS,
NØRGAARDPEDERSEN BENT
Publication year - 1987
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1987.tb03145.x
Subject(s) - amniocentesis , medicine , obstetrics , randomized controlled trial , ultrasound , gynecology , pregnancy , prenatal diagnosis , fetus , surgery , biology , genetics , radiology
Summary Maternal serum alpha‐fetoprotein (AFP) levels were determined before and after genetic amniocentesis ( n =283) or ultrasound scan ( n =268) in a group of women participating in a randomized trial of genetic amniocentesis. Increases in AFP levels were seen significantly more often after amniocentesis than after ultrasound scan ( P <0·001) and 48 women in the amniocentesis group had increases in AFP (ΔAFP) that were larger than the maximum ΔAFP (±25 μg/1) seen in the ultrasound group. If a ΔAFP of <25 μg/1 represents a feto‐maternal haemorrhage (FMH) attributable to amniocentesis, the rate of amniocentesis‐induced FMH was 17%. Such FMH was seen significantly more often after transplacental amniocentesis or after amniocentesis performed by less experienced operators. No association was detected between birthweight and FMH attributable to amniocentesis.